Anti-VEGF Therapy May Aid Visual Acuity in Some nAMD Patients
MONDAY, Oct. 19, 2020 -- For about 20 percent of patients with neovascular age-related macular degeneration (nAMD), useful visual acuity (VA) is preserved with anti-vascular endothelial growth factor (VEGF) treatment, according to a study published online Oct. 15 in JAMA Ophthalmology.
Robert P. Finger, M.D., Ph.D., from the University of Bonn in Germany, and colleagues conducted multistate modeling using real-world cohort data of 3,192 patients with nAMD treated in eye clinics in Australia, New Zealand, and Switzerland to examine VA outcomes of anti-VEGF treatment. Intravitreal anti-VEGF treatment was provided at the treating physician's discretion.
The researchers found that an estimated 12 percent of the sample retained driving VA and an estimated 15 percent retained reading VA in at least one eye for the mean remaining lifetime of 11 years. An estimated 82 percent of the sample had dropped out at that time. Better long-term outcomes were seen in association with younger age at baseline and more injections during the first year of treatment.
"Anti-VEGF treatment preserves useful VA in almost 20 percent of patients for their average remaining life span," the authors write. "Given the almost uniformly rapid progressive vision loss associated with the natural history of nAMD, this is a remarkable outcome for any chronic disease, underlining the public health necessity of providing anti-VEGF treatment to persons in need as early as possible."
Several authors disclosed financial ties to the pharmaceutical industry.
© 2021 HealthDay. All rights reserved.
Posted: October 2020
Read this next
TUESDAY, Dec. 22, 2020 -- For patients with proliferative diabetic retinopathy with vitreous hemorrhage, most outcomes do not differ significantly for initial treatment with...
FRIDAY, Dec. 18, 2020 -- Children and young teens can safely wear soft contact lenses (SCLs), according to a study recently published in Ophthalmic & Physiological Optics. In...
FRIDAY, Oct. 30, 2020 -- For initially healthy men and women, supplementation with vitamin D3 and marine omega-3 fatty acids have no significant impact on age-related macular...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.